Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Apr 11:2019:4962678.
doi: 10.1155/2019/4962678. eCollection 2019.

A Rare Case of Extramedullary Relapse of Multiple Myeloma Causing Bowel Obstruction

Affiliations
Case Reports

A Rare Case of Extramedullary Relapse of Multiple Myeloma Causing Bowel Obstruction

Prarthna V Bhardwaj et al. Case Rep Hematol. .

Abstract

Extramedullary myeloma, defined by presence of plasma cells outside the bone marrow, is a rare entity accounting for about 3-9% of all cases. It usually is aggressive with a median survival of <6 months. It is also associated with adverse prognostic factors including 17p deletions and high-risk gene profiles. While common extramedullary sites include bones, there have been several case reports of hematogenous extramedullary myeloma to the liver, lungs, pancreas, breast, skin, and soft tissues. Extramedullary myeloma to the mesentery is a rare entity with only a handful of cases reported. We present a case of 69-year-old man presenting with relapse of multiple myeloma to the mesentery, resulting in bowel obstruction to highlight the various presentations of myeloma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CT scan of the abdomen without contrast revealing mesenteric thickening with edema.
Figure 2
Figure 2
(a) Bone marrow infiltrated by plasma cells. (b) Bone marrow immunohistochemistry revealing CD138 positive cells. (c) Bone marrow immunohistochemistry positive for kappa light chains. (d) Bone marrow immunohistochemistry negative for lambda light chains. Mesenteric invasion (e) by myeloma cells (10x) and (f) by plasma cells (40x).
Figure 3
Figure 3
Lytic lesions on the skull.
Figure 4
Figure 4
Lytic lesions on the L femur.

References

    1. Ghimire K. B., Rajkumar S. V., Dispenzieri A., et al. Incidence and survival outcomes of extramedullary myeloma. Blood. 2013;122(21):p. 3141.
    1. Short K. D., Rajkumar S. V., Larson D., et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–908. doi: 10.1038/leu.2011.29. - DOI - PMC - PubMed
    1. Weinstock M., Ghobrial I. M. Extramedullary multiple myeloma. Leukemia and Lymphoma. 2013;54(6):1135–1141. doi: 10.3109/10428194.2012.740562. - DOI - PubMed
    1. Usmani S. Z., Heuck C., Mitchell A., et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761–1767. doi: 10.3324/haematol.2012.065698. - DOI - PMC - PubMed
    1. Galhotra R., Saggar K., Gupta K., Singh P. Primary isolated extramedullary plasmacytoma of the mesentery: a rare case report. Gastroenterology Research. 2012;12:81–84. - PubMed

Publication types

LinkOut - more resources